RxDoctor Payments Data

An Tran, MD

Hematology & Oncology · Cleveland, TNNPI 1366637563

Payments from drug & device makers

$7,507in general payments, 2019–2025

Across 414 payments — averaging $18.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$730
  • Merck$500
  • AstraZeneca$402
  • Gilead$358
  • Pfizer$342
  • E.r. Squibb & Sons, L.L.C.$279
  • plus $5K from 51 others

What the payments were for

  • Food & beverage$7,39198%
  • Education$1172%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,507 in reported general payments places this provider in the 35th percentile of 251 hematology & oncology providers in Tennessee.

See all hematology & oncology providers in Tennessee

Medicare billing

Part B allowed, 2024
$3,128,198
Medicare patients
683
Services billed
169,970

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide50$740,676
PomalystPomalidomide13$263,732
CalquenceAcalabrutinib Maleate14$184,479
JakafiRuxolitinib Phosphate14$150,668
Abiraterone Acetate70$142,196
PromactaEltrombopag Olamine12$81,742
Imatinib Mesylate22$66,788
VenclextaVenetoclax20$64,447
EliquisApixaban42$27,321
XareltoRivaroxaban24$13,690
Anastrozole174$3,165
Hydroxyurea62$1,423
Prochlorperazine Maleate82$1,344
Dexamethasone51$1,190
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen53$993

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$243$740,67650 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$279$263,73213 claims
AstraZenecaCalquence$402$184,47914 claims
Incyte CorporationJakafi$190$150,66814 claims
NovartisPromacta$730$81,74212 claims
AbbVieVenclexta$160$64,44720 claims
PfizerEliquis$342$27,32142 claims
Johnson & JohnsonXarelto$136$13,69024 claims
Lilly USA, LLCOlanzapine$249$41522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 251 hematology & oncology providers in Tennessee.

Other hematology & oncology in Cleveland

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →